Drug intelligence / Profile preview

PD-29875

Development stage: Preclinical
Lead developer: PeptiDream
Modality: Peptides
Administration: Intravenous

Overview

**PD-29875** is a PeptiDream-derived, highly selective macrocyclic peptide that binds **claudin 18.2**. It is the targeting component of a radiotheranostic program: the diagnostic agent **64Cu-PD-29875** is being evaluated by PET/CT in a first-in-human Phase 0 imaging study in gastric cancer and gastroesophageal junction cancer, while therapeutic versions are intended to use isotopes such as actinium-225. PD-29875 itself is the unlabeled peptide precursor and can also be labeled with lutetium-177 or other radionuclides for CLDN18.2-positive tumors. ([pdradiopharma.com](https://www.pdradiopharma.com/en/uploads/f0bc129046e4d183eaac1786cfb0f2869a89c9f3.pdf))

Other names: 225Ac/64Cu-CLDN18.2225Ac/64Cu-CLDN18.2 PD-29875

Targets

Claudin 18.2

Beyond the preview

Go deeper on PD-29875.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD-29875.

Explore the full profile